Agennix Data Published in the International Journal of Cancer; Journal Features Cover Image of Tumor Regression Following rhLF-Treatment

HOUSTON -August 18, 2004- Agennix Inc. today announced that its pre-clinical recombinant human lactoferrin (rhLF) data was published in an article entitled "Oral Lactoferrin Inhibits Growth of Established Tumors and Potentiates Conventional Chemotherapy," in the September 1st issue of the International Journal of Cancer (IJC) (Vol. 111, pp 398-403).

The publication described the anti-cancer activity of rhLF, a natural immunomodulatory protein, in pre-clinical experiments. Oral rhLF demonstrated anti-cancer activity when administered alone and in combination with chemotherapy in tumor-bearing mice. Monotherapy of a squamous cell carcinoma in a syngeneic murine model caused a 66% tumor growth inhibition that was statistically significant over placebo (p<0.01) and comparable to that obtained by therapy with Cis-platinum, docetaxel or radiotherapy. Mice receiving both rhLF and Cis-platinum showed a statistically significant improvement over either drug alone. Tumor growth inhibition with oral rhLF was also observed in a murine renal cell carcinoma model (p<0.01). In a mammary adenocarcinoma model, oral rhLF also induced tumor shrinkage including complete rejection of established tumors.

Separately, the IJC featured a cover image showing the regression of lung metastases in a patient with renal cell carcinoma (RCC) following treatment with rhLF. The patient had a durable partial response following monotherapy with rhLF after having previously progressed on a four-drug regimen with capecitabine, interferon, gemcitabine and thalidomide. Agennix is currently conducting Phase II trials in RCC and non-small cell lung cancer.

About Agennix:

Agennix, a privately owned Houston-based biopharmaceutical company, is the world leader in the development of recombinant human lactoferrin (rhLF), a natural immunomodulatory protein. Oral rhLF has been shown to be safe and well tolerated. It has also been shown to be effective in cancer, asthma and wound healing pre-clinical models, and in Phase I/II human clinical trials in cancer. Agennix is the first and only company to manufacture substantial quantities of human lactoferrin and holds global patents on its technology, with 73 issued patents, and more than 50 pending patents. Agennix has six Phase II human clinical trials currently underway in the treatment of cancer, asthma, and diabetic foot ulcers, with company sponsored U.S. INDs in each area.

More information about Agennix is available on the Company's web site at http://www.agennix.com.